Second newsletter published

The second newsletter of the PREDICTION-ADR consortium has been published. Read about the recent annual plenary meeting of the consortium held in Uppsala where the progress of the research was discussed. PREDICTION-ADR partner ASPER Biotech is now marketing a genetic test which can help predict which patients are likely to suffer adverse reactions to statins. PREDICTION-ADR research has revealed serious risks to patients of continuing ACE inhibitor therapy after suffering angioedema.  A method to improve the efficiency of studies on ACEi induced angioedema using healthcare databases has been published.  A further PREDICTION-ADR publication reports a gene variant which is associated with a common side effect of ACEi treatment. PREDICTION-ADR is also now collaborating with Danish researchers to reach a wider European population. Download Newsletter…

Leave a comment

Your email address will not be published.